Matches in SemOpenAlex for { <https://semopenalex.org/work/W339947339> ?p ?o ?g. }
- W339947339 endingPage "77" @default.
- W339947339 startingPage "69" @default.
- W339947339 abstract "Survivin is known to be overexpressed in various human malignancies, including pancreatic cancer, and mediates cancer cell proliferation and tumor growth, so the regulation of this molecule could be a new strategy for treating pancreatic cancer. In this study, short hairpin RNAs (shRNAs) specific to survivin were introduced into human pancreatic cancer Patu8988 cells to investigate the inhibitory effects on survivin expression and cell proliferation in vitro and in vivo.Three kinds of shRNA specific to the survivin gene were designed and cloned into eukaryotic expression plasmid pGenesil-1 vector. Subsequently the recombinant plasmids were transfected into human pancreatic cancer Patu8988 cells with lipfectamineTM 2000 reagent. The mRNA and protein expressions of survivin in the transiently transfected Patu8988 cells were determined by RT-PCR, flow cytometry, and Western blotting analysis. The proliferation inhibition rates of stably transfected Patu8988 cells were determined by MTT assay. The antitumor activities of the three kinds of survivin-shRNA plasmids were evaluated in BALB/c nude mice inoculated with Patu8988 cells and bearing human pancreatic cancer.The three survivin-shRNA plasmids named pGenesil-1-survivin-1, pGenesil-1-survivin-2 and pGenesil-1-survivin-1+2 (with double interfering RNA sites) were successfully constructed, and were confirmed by restriction enzyme cutting and sequencing. At 48 hours after transfection, the expression of survivin mRNA and protein was inhibited in Patu8988 cells transfected with pGenesil-1-survivin-1, pGenesil-1-survivin-2, and pGenesil-1-survivin-1+2 when compared with that of either pGenesil-1-NC (with scrambled small interfering RNA) transfected cells or control cells (P<0.05). The MTT results showed that the proliferation rates of Patu8988 cells stably transfected with survivin-shRNA plasmids were reduced when compared with that of either pGenesil-1-NC transfected cells or control cells (P<0.01). Furthermore, when Patu8988 cells stably transfected with survivin-shRNA were injected into BALB/c nude mice, tumor growth was dramatically lower and the tumor was smaller than that of either pGenesil-1-NC transfected cells or control cells (P<0.01). The inhibitory effect of pGenesil-1-survivin-1 was the best among the three kinds of survivin-shRNA plasmids, but no combination of inhibitory effects was found in pGenesil-1-survivin-1+2.shRNAs specific to survivin have gene silencing effects and inhibit pancreatic cancer cell proliferation. shRNA activity against survivin could be of potential value in gene therapy for pancreatic cancer. However, shRNAs with double combining sites did not significantly enhance the interference compared with single site shRNAs, therefore further studies on this are needed." @default.
- W339947339 created "2016-06-24" @default.
- W339947339 creator A5002085134 @default.
- W339947339 creator A5024242005 @default.
- W339947339 creator A5034058657 @default.
- W339947339 creator A5050081278 @default.
- W339947339 creator A5072490995 @default.
- W339947339 creator A5088585559 @default.
- W339947339 date "2010-02-01" @default.
- W339947339 modified "2023-09-23" @default.
- W339947339 title "Growth inhibition induced by short hairpin RNA to silence survivin gene in human pancreatic cancer cells." @default.
- W339947339 cites W1968362551 @default.
- W339947339 cites W1969075574 @default.
- W339947339 cites W1970445062 @default.
- W339947339 cites W1991761823 @default.
- W339947339 cites W2006783667 @default.
- W339947339 cites W2009477693 @default.
- W339947339 cites W2011390079 @default.
- W339947339 cites W2019546074 @default.
- W339947339 cites W2022179846 @default.
- W339947339 cites W2022969655 @default.
- W339947339 cites W2026230919 @default.
- W339947339 cites W2045859286 @default.
- W339947339 cites W2048075376 @default.
- W339947339 cites W2064559284 @default.
- W339947339 cites W2065480841 @default.
- W339947339 cites W2073490481 @default.
- W339947339 cites W2085588982 @default.
- W339947339 cites W2106403499 @default.
- W339947339 cites W2114060340 @default.
- W339947339 cites W2121280471 @default.
- W339947339 cites W2146888510 @default.
- W339947339 cites W2150579219 @default.
- W339947339 cites W2161959295 @default.
- W339947339 cites W2165178187 @default.
- W339947339 cites W2170479207 @default.
- W339947339 cites W2378298191 @default.
- W339947339 cites W2408889139 @default.
- W339947339 cites W3142373954 @default.
- W339947339 cites W43051898 @default.
- W339947339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20133233" @default.
- W339947339 hasPublicationYear "2010" @default.
- W339947339 type Work @default.
- W339947339 sameAs 339947339 @default.
- W339947339 citedByCount "3" @default.
- W339947339 countsByYear W3399473392012 @default.
- W339947339 countsByYear W3399473392015 @default.
- W339947339 crossrefType "journal-article" @default.
- W339947339 hasAuthorship W339947339A5002085134 @default.
- W339947339 hasAuthorship W339947339A5024242005 @default.
- W339947339 hasAuthorship W339947339A5034058657 @default.
- W339947339 hasAuthorship W339947339A5050081278 @default.
- W339947339 hasAuthorship W339947339A5072490995 @default.
- W339947339 hasAuthorship W339947339A5088585559 @default.
- W339947339 hasConcept C104317684 @default.
- W339947339 hasConcept C121608353 @default.
- W339947339 hasConcept C153911025 @default.
- W339947339 hasConcept C190232843 @default.
- W339947339 hasConcept C190283241 @default.
- W339947339 hasConcept C2775975398 @default.
- W339947339 hasConcept C2780210213 @default.
- W339947339 hasConcept C502942594 @default.
- W339947339 hasConcept C54009773 @default.
- W339947339 hasConcept C54355233 @default.
- W339947339 hasConcept C55493867 @default.
- W339947339 hasConcept C62112901 @default.
- W339947339 hasConcept C67705224 @default.
- W339947339 hasConcept C81885089 @default.
- W339947339 hasConcept C86803240 @default.
- W339947339 hasConcept C96232424 @default.
- W339947339 hasConceptScore W339947339C104317684 @default.
- W339947339 hasConceptScore W339947339C121608353 @default.
- W339947339 hasConceptScore W339947339C153911025 @default.
- W339947339 hasConceptScore W339947339C190232843 @default.
- W339947339 hasConceptScore W339947339C190283241 @default.
- W339947339 hasConceptScore W339947339C2775975398 @default.
- W339947339 hasConceptScore W339947339C2780210213 @default.
- W339947339 hasConceptScore W339947339C502942594 @default.
- W339947339 hasConceptScore W339947339C54009773 @default.
- W339947339 hasConceptScore W339947339C54355233 @default.
- W339947339 hasConceptScore W339947339C55493867 @default.
- W339947339 hasConceptScore W339947339C62112901 @default.
- W339947339 hasConceptScore W339947339C67705224 @default.
- W339947339 hasConceptScore W339947339C81885089 @default.
- W339947339 hasConceptScore W339947339C86803240 @default.
- W339947339 hasConceptScore W339947339C96232424 @default.
- W339947339 hasIssue "1" @default.
- W339947339 hasLocation W3399473391 @default.
- W339947339 hasOpenAccess W339947339 @default.
- W339947339 hasPrimaryLocation W3399473391 @default.
- W339947339 hasRelatedWork W2100159657 @default.
- W339947339 hasRelatedWork W2188463817 @default.
- W339947339 hasRelatedWork W2350600457 @default.
- W339947339 hasRelatedWork W2368179648 @default.
- W339947339 hasRelatedWork W2372360998 @default.
- W339947339 hasRelatedWork W2387438353 @default.
- W339947339 hasRelatedWork W2412750807 @default.
- W339947339 hasRelatedWork W2417790292 @default.